Pulse Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Arthur LaViolette
- Full Time Employees
- 75
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 3957 Point Eden Way Miami CA United States of America 94545
- IPO Date
- May 18, 2016
- CIK
- 0001625101
- Website
- pulsebiosciences.com
- Similar Companies
- Business
- Pulse Biosciences, Inc. engages in the development and commercialization of innovative bioelectric technology platforms for use in medical aesthetic and oncology applications. The company's core products include the Nano-Pulse Stimulation (NPS) platform and the CellFX System, which deliver ultrashort electrical pulses to target and treat various cellular abnormalities. These technologies are employed for aesthetic procedures such as the treatment of sebaceous hyperplasia, warts, and other dermatological conditions, as well as for emerging oncology indications. Pulse Biosciences offers its products primarily in the United States, with operations extending to selected international markets. Founded in 2011, the company is headquartered in Hayward, California. In terms of recent developments within the last 1-2 years, Pulse Biosciences has focused on expanding the applications of its NPS technology through clinical trials and regulatory progress towards new indications, including oncology treatments. The company has made strategic partnerships and commenced new clinical evaluations to broaden the commercial use of its CellFX System. These initiatives mark a significant expansion beyond its initial dermatology and medical aesthetics focus, emphasizing the company's commitment to advancing innovative, non-thermal, tissue-selective therapies. There have been no major name changes or reorganizations reported recently, but the company continues to align its product development with evolving market needs in both aesthetic medicine and oncology. Pulse Biosciences operates in the medical technology industry, specifically within the segments of medical aesthetics and oncology device manufacturing. Its target markets include dermatology clinics, medical aesthetic centers, and oncology treatment facilities. The company develops and sells its products through direct sales and partnerships, aiming to provide minimally invasive treatment options that reduce patient downtime and side effects compared to conventional treatments. In summary, Pulse Biosciences, Inc. specializes in the manufacture and commercialization of bioelectric pulse-mediated medical technologies such as the CellFX System and related products, serving aesthetic and oncology markets with innovative tissue-targeting therapies primarily in the United States and internationally. Its ongoing clinical and commercial expansion efforts and strategic partnerships highlight the company's focus on broadening the applications of its proprietary bioelectric technology platform. The company was established in 2011 and is headquartered in Hayward, California. [web:search results synthesized]
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
Pulse Biosciences Q1 Earnings Call Highlights
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call Transcript
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
Pulse Biosciences to Host Analyst Event on April 25, 2026
Argo Wealth Advisory LLC Makes New $387,000 Investment in Pulse Biosciences, Inc $PLSE
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study
Pulse Biosciences Strengthens Executive Leadership Team
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference